Brazil Alzheimer’s Disease Drugs Market Report 2022 to 2030

Brazil Alzheimer’s Disease Drugs Market Analysis

$ 3999

Brazil's Alzheimer’s disease drugs market was valued at $386 Mn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $792 Mn in 2030. One of the main reasons propelling the growth of this market is government support technologies and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Abbvie, AstraZeneca, Aspen, Bristol Myers Squibb, Chiesi Farmaceutici, Daiichi Sankyo Company, Eisai Co., Eurofarma, Ferring, Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.

ID: IN10BRPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Nandini Shah

Buy Now

Brazil Alzheimer’s Disease Drugs Market Executive Summary

The Brazil Alzheimer’s Disease Drugs market was valued at $386 Mn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022 to 2030 and will reach $792 Mn in 2030. Alzheimer's disease is an irreversible brain disorder that impairs memory, thinking, and behavior. It is the leading cause of dementia, accounting for 60-70% of all cases. Alzheimer's disease is characterized by the accumulation of aberrant protein deposits in the brain, which causes brain cell death and progressive loss of cognitive function. Early Alzheimer's disease symptoms may include trouble remembering recent events, disorientation, personality changes, and language and communication impairments. Individuals may have severe memory loss, confusion, mood fluctuations, and difficulties with basic daily activities as the condition develops.

Dementia is the most frequent neurological disease in the senior population, according to the most recent Alzheimer's Disease International report. It affects 50Mn individuals worldwide and is anticipated to quadruple by 2050. More than half of all people with dementia live in low- and middle-income countries, where only 10% of individuals receive an adequate diagnosis. Alzheimer's disease (AD) is the most common dementia, accounting for 50-70% of cases. AD is a neurodegenerative disease that causes cognitive impairment as well as progressive degradation of intellectual and everyday skills. In Brazil, it is estimated that 6% of the 15Mn persons over the age of 60 suffer from Alzheimer's disease.

brazil alzheimers disease drugs market

Market Dynamics

Market Growth Drivers

Brazil, like many other countries, is experiencing an aging population, with the number of people aged 60 and over expected to double by 2050. As a result, the prevalence of Alzheimer's disease and related dementias is expected to increase, leading to a higher demand for Alzheimer's drugs. There is a growing awareness of Alzheimer's disease and related dementias in Brazil, with more people seeking diagnosis and treatment for these conditions. This increased awareness is driving demand for Alzheimer's drugs. Brazil has made significant investments in its healthcare infrastructure in recent years, including expanding access to medical facilities and increasing the number of trained healthcare professionals. This has led to better detection, diagnosis, and treatment of Alzheimer's disease and related dementias, driving demand for Alzheimer's drugs.

There is ongoing research and development of new drugs for Alzheimer's disease, which may offer more effective treatment options. As these drugs are introduced to the market, they may drive growth in the Alzheimer's drugs market in Brazil. The Brazilian government has implemented several initiatives to improve access to healthcare, including funding for Alzheimer's research and providing subsidies for certain drugs. These initiatives are expected to drive growth in the Alzheimer's drugs market.

Market Restraints

Alzheimer's disease and related dementias are often underdiagnosed and misdiagnosed, particularly in low- and middle-income countries like Brazil. This can result in inaccurate data on the prevalence and incidence of these conditions. There is limited data collection on Alzheimer's disease and related dementias in Brazil, particularly in rural and remote areas. This can result in incomplete or inaccurate data on the prevalence, incidence, and impact of these conditions. Stigma and cultural factors may prevent individuals and their families from seeking medical help for Alzheimer's disease and related dementias, leading to underreporting and inaccurate data. There is a lack of standardization in the diagnostic criteria and assessment tools used to diagnose Alzheimer's disease and related dementias in Brazil. This can result in variability in data collection and reporting across different healthcare providers and institutions. There is a relatively limited amount of research on Alzheimer's disease and related dementias in Brazil, particularly in comparison to other countries. This can result in a lack of knowledge and understanding of the prevalence, incidence, and impact of these conditions in the Brazilian context.

Competitive Landscape

Key Players

Abbvie
AstraZeneca
Aspen
Bristol Myers Squibb
Chiesi Farmaceutici
Daiichi Sankyo Company
Eisai Co.
Eurofarma
Ferring
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
F. Hoffmann-La Roche AG
Merck & Co.
Novartis
Pfizer

Healthcare Policies and Regulatory Landscape

The Brazilian Ministry of Health provides free access to some Alzheimer's drugs for eligible patients through the Unified Health System (SUS). The drugs covered include cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine, as well as memantine. The Brazilian government has established a National Alzheimer's Disease Plan, which aims to improve the diagnosis, treatment, and care of people with Alzheimer's disease and related dementias. The plan includes initiatives such as increasing access to diagnosis and treatment, promoting research and providing training for healthcare professionals. The Brazilian Health Regulatory Agency (ANVISA) is responsible for regulating the pharmaceutical industry and approving new drugs for use in Brazil. ANVISA evaluates the safety, efficacy, and quality of drugs before they are approved for use in the country.

The Brazilian government provides funding for research into Alzheimer's disease and related dementias, including basic research, clinical trials, and translational research. It also provides subsidies for some Alzheimer's drugs through the Farmácia Popular program, which aims to improve access to essential medicines for low-income families.

Reimbursement Scenario

The SUS provides free access to some Alzheimer's drugs for eligible patients, including cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine, as well as memantine. The drugs are provided through the SUS's Essential Medicines Program, which aims to ensure access to essential medicines for all Brazilian citizens. Private health insurance companies may provide coverage for Alzheimer's drugs, but the level of coverage and reimbursement may vary depending on the specific insurance plan. Patients should check with their insurance company to determine their level of coverage. The Brazilian government's Farmácia Popular program provides subsidies for some essential medicines, including some Alzheimer's drugs. Eligible patients can purchase these drugs at a reduced cost at participating pharmacies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer’s Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion):

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.